Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2007

View Archived Issues

Novel therapeutic agents for Alzheimer's disease reported in recent AstraZeneca patent

Recent Takeda patent reports novel tachykinin NK1 antagonists

Cudraflavanone A antitumor mechanism identified

TZB-30878 shows potential for IBS in preclinical studies

Abbott continues to develop novel multitargeted RTK inhibitors

Oral efficacy of new MIF inhibitor in animal models of inflammatory diseases

Lorus Therapeutics reports year end results for 2007

AGI Therapeutics licenses compound with potential for GI-related applications

Takeda's TAK-536 enters phase II for treatment of hypertension in Japan

Promising phase II clinical trial results for Reviroc

Plans delayed for phase III study of bremelanotide for ED

YM BioSciences to begin phase II trial of nimotuzumab for DIPG

FDA approves Omrix's BLA for thrombin stand alone topical Evithrom

Novel non-nucleoside HIV reverse transcriptase inhibitors profiled at Roche

Optimization of natural Chinese medicine leads to potential treatment for alcohol addiction

Cardiome Pharma and Astellas Pharma announce PDUFA extension

Karo Bio provides update of internal projects

Positive phase II trial results for Histalean in obese women under 50

Potential efficacy of amphotericin B-containing hydrogel against intravascular catheter infections

Pfizer discloses novel antibacterial agents in recent patents

Novel agents for HCV infection reported in recent Wyeth and GSK patents

First patient dosed in Opko's pivotal phase III bevasiranib trial for wet AMD

Sunesis reorganizes drug development focus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...